References
- Bennett J. M., Catovsky D., Daniel M. T., Flandrin G., Galton D. A. G., Gralnick H. R., Sultan C. Proposed revised criteria for the classification of acute my-eloid leukemia. Ann. Intern. Med. 1985; 103: 626–629
- Bennett J. M., Catovsky D., Daniel M. T., Flandrin G., Galton D. A. G., Gralnick H. R., Sultan C. Proposals for the classification of the myelodysplastic syndromes. Br. J. Haematol. 1982; 51: 189–199
- Estey E. H., Keating M. J., Dixon D. O., Trujillo J. M., McCredie K. B., Freireich E. J. Karyotype is prognostically more important than the FAB system's distinction between myelodysplastic syndrome and acute my-elogenous leukemia. Hematol. Pathol. 1987; 1: 203–208
- Estey E., Plunkett W., Gandhi V., Rios M., Kantarjian H., Keating M. Fludarabine and arabinosylcyto-sine therapy for refractory and relapsed acute myelogenous leukemia. Leukemia and Lymphoma 1993; 9: 343–350
- Gandhi V., Estey E., Keating M. J., Plunkett W. Fludarabine potentiates metabolism of arabinosyl cytosione in patients with acute myelogenous leukemia during therapy. J. Clin. Oncol. 1993; 11: 116–124
- Keating M. J., Smith T. L., Kantarjian H., Cork A., Walters R., Trujillo J. M., McCredie K. B., Gehan E. A., Freireich E. J. Cytogenetic pattern in acute myelog-enous leukemia. A major reproducible determinant of outcome. Leukemia 1988; 2: 403–412
- Rheingold J. J., Kaufman R., Adelson E., Lear A. Smoldering acute leukemia. N. Engl. J. Med. 1963; 268: 812–815
- Rheingold J. J. Acute leukemia, its smoldering phase or leukemia never starts on thursday. J. Am. Med. Assoc. 1974; 230: 985–986
- Estey E. H., Trujillo J. M., Cork A., O'Brien S., Beran M., Kantarjian H., Keating M., Freireich E. J., Stass S. AML-associated cytogenetic abnormalities (inv (16), del (16), t(8;21)) in patients with myelodysplastic syndromes. Hematol. Pathol. 1992; 6: 43–48
- Mertelsmann R., Thaler H. T., To L. Morphological classification, response to therapy, and survival in 263 adult patients with acute nonlymphoblastic leukemia. Blood 1980; 56: 773–181
- Armitage J. O., Dick F. R., Needleman S. W., et al. Effect of chemotherapy for the dysmyelopoietic syndrome. Cancer Treat. Rep. 1981; 65: 601–605
- Tricot G., Boogaerts M. A. The role of aggressive chemotherapy in the treatment of the myelodysplastic syndromes. Br. J. Haematol. 1986; 63: 477–483
- Fenaux P., Lai J. L., Jouet J. P., et al. Aggressive chemotherapy in adult primary myelodysplastic syndromes. Blut 1988; 57: 297–302
- Fenaux P., Morel P., Rose C., et al. Prognostic factors in adult de novo myelodysplastic syndromes treated by intestive chemotherapy. Br. J. Haematol. 1991; 77: 497–501
- Michels S. D., Saumur J., Arthur D. C., et al. Refractory anemia with excess of blasts in transformation-he-matologic and clinical study of 52 patients. Cancer 1989; 64: 2340–2346